Search Articles

View query in Help articles search

Search Results (1 to 2 of 2 Results)

Download search results: CSV END BibTex RIS


The Safety, Clinical, and Neurophysiological Effects of Intranasal Ketamine in Patients Who Do Not Respond to Electroconvulsive Therapy: Protocol for a Pilot, Open-Label Clinical Trial

The Safety, Clinical, and Neurophysiological Effects of Intranasal Ketamine in Patients Who Do Not Respond to Electroconvulsive Therapy: Protocol for a Pilot, Open-Label Clinical Trial

Intranasal drug delivery, while preserving the rapid onset of therapeutic action, offers a route to the brain that bypasses problems associated with gastrointestinal absorption, first-pass metabolism, and the blood-brain barrier, and thus, minimizes the inconvenience and discomfort of parenteral administration [14]. Studies [15] indicate that intranasal rketamine has an absolute bioavailability of 50%, with a maximum plasma concentration achieved at approximately 20 minutes.

Yuliya Knyahnytska, Reza Zomorrodi, Tyler Kaster, Daphne Voineskos, Alisson Trevizol, Daniel Blumberger

JMIR Res Protoc 2022;11(1):e30163

The Quality of Instructional YouTube Videos for the Administration of Intranasal Spray: Observational Study

The Quality of Instructional YouTube Videos for the Administration of Intranasal Spray: Observational Study

When the symptoms are persistent, the recommended treatment for allergic rhinitis consists of administration of intranasal corticosteroid sprays [7-9]. It is important to administer the nasal spray in the correct technical manner. A recent study has shown that only 6% of the patients used the correct administration technique of intranasal corticosteroid sprays as described in the patient information leaflet [10].

Marije M Peters-Geven, Corine Rollema, Esther I Metting, Eric N van Roon, Tjalling W de Vries

JMIR Med Educ 2020;6(2):e23668